Home World News FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma World News FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 358 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Rucaparib October 27, 2023 FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine... July 29, 2026 EMA Recommends Extension of Therapeutic Indications for Tislelizumab June 7, 2024 FDA Approves Osimertinib for Locally Advanced, Unresectable Stage III Non-Small Cell... October 8, 2024 Load more HOT NEWS Does Too Much Fructose Help Colorectal Cancers Grow? Early Evaluation of Nutritional Status Is Needed to Provide Nutritional Support... Exercising Safely During Breast Cancer Treatment: What to Know Καρκίνος οισοφάγου